ADVENTRX Announces Completion Of Patient Enrollment In ANX-530 Marketing-Enabling Clinical Study

ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced that it has completed patient enrollment in its marketing-enabling clinical study of ANX-530 (vinorelbine emulsion), a novel, emulsion formulation of vinorelbine tartrate. [click link for full article]

More: continued here

Filed under: Clinical Trials on October 11th, 2007